<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30755025</PMID><DateCompleted><Year>2020</Year><Month>03</Month><Day>02</Day></DateCompleted><DateRevised><Year>2020</Year><Month>05</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1524-4539</ISSN><JournalIssue CitedMedium="Internet"><Volume>139</Volume><Issue>20</Issue><PubDate><Year>2019</Year><Month>May</Month><Day>14</Day></PubDate></JournalIssue><Title>Circulation</Title><ISOAbbreviation>Circulation</ISOAbbreviation></Journal><ArticleTitle>Enterovirus Persistence in Cardiac Cells of Patients With Idiopathic Dilated Cardiomyopathy Is Linked to 5' Terminal Genomic RNA-Deleted Viral Populations With Viral-Encoded Proteinase Activities.</ArticleTitle><Pagination><StartPage>2326</StartPage><EndPage>2338</EndPage><MedlinePgn>2326-2338</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1161/CIRCULATIONAHA.118.035966</ELocationID><Abstract><AbstractText Label="BACKGROUND">Group B enteroviruses are common causes of acute myocarditis, which can be a precursor of chronic myocarditis and dilated cardiomyopathy, leading causes of heart transplantation. To date, the specific viral functions involved in the development of dilated cardiomyopathy remain unclear.</AbstractText><AbstractText Label="METHODS">Total RNA from cardiac tissue of patients with dilated cardiomyopathy was extracted, and sequences corresponding to the 5' termini of enterovirus RNAs were identified. After next-generation RNA sequencing, viral cDNA clones mimicking the enterovirus RNA sequences found in patient tissues were generated in vitro, and their replication and impact on host cell functions were assessed on primary human cardiac cells in culture.</AbstractText><AbstractText Label="RESULTS">Major enterovirus B populations characterized by 5' terminal genomic RNA deletions ranging from 17 to 50 nucleotides were identified either alone or associated with low proportions of intact 5' genomic termini. In situ hybridization and immunohistological assays detected these persistent genomes in clusters of cardiomyocytes. Transfection of viral RNA into primary human cardiomyocytes demonstrated that deleted forms of genomic RNAs displayed early replication activities in the absence of detectable viral plaque formation, whereas mixed deleted and complete forms generated particles capable of inducing cytopathic effects at levels distinct from those observed with full-length forms alone. Moreover, deleted or full-length and mixed forms of viral RNA were capable of directing translation and production of proteolytically active viral proteinase 2A in human cardiomyocytes.</AbstractText><AbstractText Label="CONCLUSIONS">We demonstrate that persistent viral forms are composed of B-type enteroviruses harboring a 5' terminal deletion in their genomic RNAs and that these viruses alone or associated with full-length populations of helper RNAs could impair cardiomyocyte functions by the proteolytic activity of viral proteinase 2A in cases of unexplained dilated cardiomyopathy. These results provide a better understanding of the molecular mechanisms that underlie the persistence of EV forms in human cardiac tissues and should stimulate the development of new therapeutic strategies based on specific inhibitors of the coxsackievirus B proteinase 2A activity for acute and chronic cardiac infections.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bouin</LastName><ForeName>Alexis</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>EA-4684 Cardiovir, Faculty of Medicine, University of Reims Champagne-Ardenne, Reims, France (A.B., P.-A.G., M.W., F.R., Y.N., A.R., P.F., L.A.).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology and Molecular Genetics, School of Medicine, University of California, Irvine (A.B., M.N.V., B.L.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gretteau</LastName><ForeName>Paul-Antoine</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>EA-4684 Cardiovir, Faculty of Medicine, University of Reims Champagne-Ardenne, Reims, France (A.B., P.-A.G., M.W., F.R., Y.N., A.R., P.F., L.A.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wehbe</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>EA-4684 Cardiovir, Faculty of Medicine, University of Reims Champagne-Ardenne, Reims, France (A.B., P.-A.G., M.W., F.R., Y.N., A.R., P.F., L.A.).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre AZM pour la recherche en biotechnologie et ses applications, Universit&#xe9; Libanaise, Tripoli, Lebanon (M.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Renois</LastName><ForeName>Fanny</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>EA-4684 Cardiovir, Faculty of Medicine, University of Reims Champagne-Ardenne, Reims, France (A.B., P.-A.G., M.W., F.R., Y.N., A.R., P.F., L.A.).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>LUNAM University, Oniris, LABERCA, UMR INRA 1329, Nantes, France (F.R.).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CHU Robert Debr&#xe9;, Laboratoire de Virologie M&#xe9;dicale et Mol&#xe9;culaire, Reims, France (F.R., Y.N., N.L., P.F., L.A.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>N'Guyen</LastName><ForeName>Yohan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>EA-4684 Cardiovir, Faculty of Medicine, University of Reims Champagne-Ardenne, Reims, France (A.B., P.-A.G., M.W., F.R., Y.N., A.R., P.F., L.A.).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CHU Robert Debr&#xe9;, Laboratoire de Virologie M&#xe9;dicale et Mol&#xe9;culaire, Reims, France (F.R., Y.N., N.L., P.F., L.A.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xe9;v&#xea;que</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>CHU Robert Debr&#xe9;, Laboratoire de Virologie M&#xe9;dicale et Mol&#xe9;culaire, Reims, France (F.R., Y.N., N.L., P.F., L.A.).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>EA-4331 LITEC, Faculty of Medicine and Pharmacy, University Hospital of Poitiers, France (N.L.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vu</LastName><ForeName>Michelle N</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Molecular Genetics, School of Medicine, University of California, Irvine (A.B., M.N.V., B.L.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tracy</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha (S.T., N.M.C.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chapman</LastName><ForeName>Nora M</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha (S.T., N.M.C.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bruneval</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Service d'Anatomie Pathologique, H&#xf4;pital Europ&#xe9;en Georges Pompidou, Paris, France (P.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fornes</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>EA-4684 Cardiovir, Faculty of Medicine, University of Reims Champagne-Ardenne, Reims, France (A.B., P.-A.G., M.W., F.R., Y.N., A.R., P.F., L.A.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Semler</LastName><ForeName>Bert L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Molecular Genetics, School of Medicine, University of California, Irvine (A.B., M.N.V., B.L.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andreoletti</LastName><ForeName>Laurent</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>EA-4684 Cardiovir, Faculty of Medicine, University of Reims Champagne-Ardenne, Reims, France (A.B., P.-A.G., M.W., F.R., Y.N., A.R., P.F., L.A.).</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI022693</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI026765</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AI026765</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Circulation</MedlineTA><NlmUniqueID>0147763</NlmUniqueID><ISSNLinking>0009-7322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020121">5' Untranslated Regions</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018076">DNA, Complementary</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D003546">Cysteine Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.29</RegistryNumber><NameOfSubstance UI="C057400">picornain 2A, Picornavirus</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Circulation. 2019 May 14;139(20):2339-2341. doi: 10.1161/CIRCULATIONAHA.119.040037</RefSource><PMID Version="1">31082299</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D020121" MajorTopicYN="N">5' Untranslated Regions</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002311" MajorTopicYN="N">Cardiomyopathy, Dilated</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003546" MajorTopicYN="N">Cysteine Endopeptidases</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003588" MajorTopicYN="N">Cytopathogenic Effect, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018076" MajorTopicYN="N">DNA, Complementary</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029822" MajorTopicYN="N">Enterovirus B, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation &amp; purification</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059014" MajorTopicYN="N">High-Throughput Nucleotide Sequencing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009205" MajorTopicYN="N">Myocarditis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D032383" MajorTopicYN="N">Myocytes, Cardiac</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017384" MajorTopicYN="N">Sequence Deletion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017735" MajorTopicYN="N">Virus Latency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">dilated cardiomyopathy</Keyword><Keyword MajorTopicYN="N">enterovirus</Keyword><Keyword MajorTopicYN="N">genomic RNA deletion</Keyword><Keyword MajorTopicYN="N">genomics</Keyword><Keyword MajorTopicYN="N">infection</Keyword><Keyword MajorTopicYN="N">persistent infection</Keyword><Keyword MajorTopicYN="N">viral 2A protease</Keyword><Keyword MajorTopicYN="N">viruses</Keyword></KeywordList><CoiStatement>Disclosure. None of the authors of the present manuscript have a commercial or other association that might pose a conflict of interest (<i>e.g</i>., pharmaceutical stock ownership, consultancy).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>5</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30755025</ArticleId><ArticleId IdType="mid">NIHMS1525146</ArticleId><ArticleId IdType="pmc">PMC6517084</ArticleId><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.118.035966</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Racaniello VR. Picornaviridae&#x202f;: The viruses and Their Replication In: Fields Virology. New York: Knipe &amp; Howley; 2007. p. 795&#x2013;838.</Citation></Reference><Reference><Citation>Dennert R, Crijns HJ, Heymans S. Acute viral myocarditis. Eur Heart J. 2008;29:2073&#x2013;2082.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2519249</ArticleId><ArticleId IdType="pubmed">18617482</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Bourlet T, Andreoletti L, Mosnier JF, Peng T, Yang Y, Archard LC, Pozzetto B, Zhang H. Enteroviral capsid protein VP1 is present in myocardial tissues from some patients with myocarditis or dilated cardiomyopathy. Circulation. 2000;101:231&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">10645916</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen Y, Renois F, Leveque N, Giusti D, Picard-Maureau M, Bruneval P, Fornes P, Andreoletti L. Virus detection and semiquantitation in explanted heart tissues of idiopathic dilated cardiomyopathy adult patients by use of PCR coupled with mass spectrometry analysis. J Clin Microbiol. 2013;51:2288&#x2013;2294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3697695</ArticleId><ArticleId IdType="pubmed">23658274</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman NM, Kim K-S, Drescher KM, Oka K, Tracy S. 5&#x2019; terminal deletions in the genome of a coxsackievirus B2 strain occurred naturally in human heart. Virology. 2008;375:480&#x2013;491.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2440640</ArticleId><ArticleId IdType="pubmed">18378272</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K-S, Tracy S, Tapprich W, Bailey J, Lee C-K, Kim K, Barry WH, Chapman NM. 5&#x2019;-Terminal deletions occur in coxsackievirus B3 during replication in murine hearts and cardiac myocyte cultures and correlate with encapsidation of negative-strand viral RNA. J Virol. 2005;79:7024&#x2013;7041.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1112132</ArticleId><ArticleId IdType="pubmed">15890942</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogt DA, Andino R. An RNA element at the 5&#x2019;-end of the poliovirus genome functions as a general promoter for RNA synthesis. PLoS Pathog. 2010;6:e1000936.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2880563</ArticleId><ArticleId IdType="pubmed">20532207</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaramillo L, Smithee S, Tracy S, Chapman NM. Domain I of the 5&#x2032; non-translated genomic region in coxsackievirus B3 RNA is not required for productive replication. Virology. 2016;496:127&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">27289561</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouin A, Nguyen Y, Wehbe M, Renois F, Fornes P, Bani-Sadr F, Metz D, Andreoletti L. Major Persistent 5&#x2032; Terminally Deleted Coxsackievirus B3 Populations in Human Endomyocardial Tissues. Emerg Infect Dis. 2016;22:1488&#x2013;1490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4982168</ArticleId><ArticleId IdType="pubmed">27434549</ArticleId></ArticleIdList></Reference><Reference><Citation>Border&#xed;a AV, Isakov O, Moratorio G, Henningsson R, Ag&#xfc;era-Gonz&#xe1;lez S, Organtini L, Gn&#xe4;dig NF, Blanc H, Alcover A, Hafenstein S, Fontes M, Shomron N, Vignuzzi M. Group Selection and Contribution of Minority Variants during Virus Adaptation Determines Virus Fitness and Phenotype. PLOS Pathog. 2015;11:e1004838.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4420505</ArticleId><ArticleId IdType="pubmed">25941809</ArticleId></ArticleIdList></Reference><Reference><Citation>Collis PS, O&#x2019;Donnell BJ, Barton DJ, Rogers JA, Flanegan JB. Replication of poliovirus RNA and subgenomic RNA transcripts in transfected cells. J Virol. 1992;66:6480&#x2013;6488.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC240140</ArticleId><ArticleId IdType="pubmed">1328676</ArticleId></ArticleIdList></Reference><Reference><Citation>Badorff C, Lee GH, Lamphear BJ, Martone ME, Campbell KP, Rhoads RE, Knowlton KU. Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat Med. 1999;5:320&#x2013;326.</Citation><ArticleIdList><ArticleId IdType="pubmed">10086389</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong D, Yajima T, Lim B-K, Stenbit A, Dublin A, Dalton ND, Summers-Torres D, Molkentin JD, Duplain H, Wessely R, Chen J, Knowlton KU. Inducible cardiac-restricted expression of enteroviral protease 2A is sufficient to induce dilated cardiomyopathy. Circulation. 2007;115:94&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">17190866</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnabei MS, Sjaastad FV, Townsend D, Bedada FB, Metzger JM. Severe dystrophic cardiomyopathy caused by the enteroviral protease 2A-mediated C-terminal dystrophin cleavage fragment. Sci Transl Med. 2015;7:294ra106.</Citation><ArticleIdList><ArticleId IdType="pubmed">26136477</ArticleId></ArticleIdList></Reference><Reference><Citation>Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, Dubourg O, K&#xfc;hl U, Maisch B, McKenna WJ, Monserrat L, Pankuweit S, Rapezzi C, Seferovic P, Tavazzi L, Keren A. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008;29:270&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pubmed">17916581</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#x2019;Guyen Y, Lesaffre F, Metz D, Tassan S, Saade Y, Boulagnon C, Fornes P, Renois F, Andreoletti L. Enterovirus but not Parvovirus B19 is associated with idiopathic dilated cardiomyopathy and endomyocardial CD3, CD68, or HLA-DR expression: Virus &amp; Inflammatory Marker Detection in DCM. J Med Virol. 2017;89:55&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">27301802</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrick DM, Mehaffey MG, Sachs MC, Altekruse S, Camalier C, Chuaqui R, Cozen W, Das B, Hernandez BY, Lih C-J, others. Robustness of next generation sequencing on older formalin-fixed paraffin-embedded tissue. PloS One. 2015;10:e0127353.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4519244</ArticleId><ArticleId IdType="pubmed">26222067</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu Z, Chapman NM, Hufnagel G, Tracy S, Romero JR, Barry WH, Zhao L, Currey K, Shapiro B. The cardiovirulent phenotype of coxsackievirus B3 is determined at a single site in the genomic 5&#x2019; nontranslated region. J Virol. 1995;69:4607&#x2013;4618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC189260</ArticleId><ArticleId IdType="pubmed">7609025</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin U, Jarasch N, Nestler M, Rassmann A, Munder T, Seitz S, Zell R, Wutzler P, Henke A. Antiviral effects of pan-caspase inhibitors on the replication of coxsackievirus B3. Apoptosis Int J Program Cell Death. 2007;12:525&#x2013;533.</Citation><ArticleIdList><ArticleId IdType="pubmed">17211569</ArticleId></ArticleIdList></Reference><Reference><Citation>Marissen WE, Lloyd RE. Eukaryotic translation initiation factor 4G is targeted for proteolytic cleavage by caspase 3 during inhibition of translation in apoptotic cells. Mol Cell Biol. 1998;18:7565&#x2013;7574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC109337</ArticleId><ArticleId IdType="pubmed">9819442</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu SF, Lloyd RE. Identification of essential amino acid residues in the functional activity of poliovirus 2A protease. Virology. 1991;182:615&#x2013;625.</Citation><ArticleIdList><ArticleId IdType="pubmed">1850921</ArticleId></ArticleIdList></Reference><Reference><Citation>Tershak DR. Inhibition of poliovirus polymerase by guanidine in vitro. J Virol. 1982;41:313&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC256753</ArticleId><ArticleId IdType="pubmed">6283124</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo J, Quinn KK, Kye S, Cooper P, Damoiseaux R, Krogstad P. Fluoxetine Is a Potent Inhibitor of Coxsackievirus Replication. Antimicrob Agents Chemother. 2012;56:4838&#x2013;4844.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3421851</ArticleId><ArticleId IdType="pubmed">22751539</ArticleId></ArticleIdList></Reference><Reference><Citation>Leveque N, Van Haecke A, Renois F, Boutolleau D, Talmud D, Andreoletti L. Rapid virological diagnosis of central nervous system infections by use of a multiplex reverse transcription-PCR DNA microarray. J Clin Microbiol. 2011;49:3874&#x2013;3879.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3209095</ArticleId><ArticleId IdType="pubmed">21918017</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter BL, Parsley TB, Ehrenfeld E, Semler BL. Distinct poly(rC) binding protein KH domain determinants for poliovirus translation initiation and viral RNA replication. J Virol. 2002;76:12008&#x2013;12022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC136902</ArticleId><ArticleId IdType="pubmed">12414943</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xe9;v&#xea;que N, Garcia M, Bouin A, Nguyen JHC, Tran GP, Andreoletti L, Semler BL. Functional Consequences of RNA 5&#x2032;-Terminal Deletions on Coxsackievirus B3 RNA Replication and Ribonucleoprotein Complex Formation. J Virol. 2017;91:e00423&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5533909</ArticleId><ArticleId IdType="pubmed">28539455</ArticleId></ArticleIdList></Reference><Reference><Citation>Bock C-T, Klingel K, Kandolf R. Human parvovirus B19-associated myocarditis. N Engl J Med. 2010;362:1248&#x2013;1249.</Citation><ArticleIdList><ArticleId IdType="pubmed">20357294</ArticleId></ArticleIdList></Reference><Reference><Citation>Leveque N, Renois F, Talmud D, Nguyen Y, Lesaffre F, Boulagnon C, Bruneval P, Fornes P, Andreoletti L. Quantitative Genomic and Antigenomic Enterovirus RNA Detection in Explanted Heart Tissue Samples from Patients with End-Stage Idiopathic Dilated Cardiomyopathy. J Clin Microbiol. 2012;50:3378&#x2013;3380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3457437</ArticleId><ArticleId IdType="pubmed">22837323</ArticleId></ArticleIdList></Reference><Reference><Citation>Giachetti C, Semler BL. Role of a viral membrane polypeptide in strand-specific initiation of poliovirus RNA synthesis. J Virol. 1991;65:2647&#x2013;2654.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC240623</ArticleId><ArticleId IdType="pubmed">1850038</ArticleId></ArticleIdList></Reference><Reference><Citation>Novak JE, Kirkegaard K. Improved method for detecting poliovirus negative strands used to demonstrate specificity of positive-strand encapsidation and the ratio of positive to negative strands in infected cells. J Virol. 1991;65:3384&#x2013;3387.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC241002</ArticleId><ArticleId IdType="pubmed">1851886</ArticleId></ArticleIdList></Reference><Reference><Citation>Lloyd RE. Translational control by viral proteinases. Virus Res. 2006;119:76&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7173276</ArticleId><ArticleId IdType="pubmed">16303201</ArticleId></ArticleIdList></Reference><Reference><Citation>Chase AJ, Semler BL. Viral subversion of host functions for picornavirus translation and RNA replication. Future Virol. 2012;7:179&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3535308</ArticleId><ArticleId IdType="pubmed">23293659</ArticleId></ArticleIdList></Reference><Reference><Citation>Tracy S, Drescher KM, Chapman NM. Enteroviruses and type 1 diabetes. Diabetes Metab Res Rev. 2011;27:820&#x2013;823.</Citation><ArticleIdList><ArticleId IdType="pubmed">22069266</ArticleId></ArticleIdList></Reference><Reference><Citation>Andr&#xe9;oletti L, L&#xe9;v&#xea;que N, Boulagnon C, Brasselet C, Fornes P. Viral causes of human myocarditis. Arch Cardiovasc Dis. 2009;102:559&#x2013;568.</Citation><ArticleIdList><ArticleId IdType="pubmed">19664576</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowles NE, Richardson PJ, Olsen EG, Archard LC. Detection of Coxsackie-B-virus-specific RNA sequences in myocardial biopsy samples from patients with myocarditis and dilated cardiomyopathy. Lancet. 1986;1:1120&#x2013;1123.</Citation><ArticleIdList><ArticleId IdType="pubmed">2871380</ArticleId></ArticleIdList></Reference><Reference><Citation>Fairweather D, Stafford KA, Sung YK. Update on coxsackievirus B3 myocarditis. Curr Opin Rheumatol. 2012;24:401&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4536812</ArticleId><ArticleId IdType="pubmed">22488075</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper LT Jr. Myocarditis. N Engl J Med. 2009;360:1526&#x2013;1538.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5814110</ArticleId><ArticleId IdType="pubmed">19357408</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreoletti L, Wattre P, Decoene C, Lobert PE, Dewilde A, Hober D. Detection of enterovirus-specific RNA sequences in explanted myocardium biopsy specimens from patients with dilated or ischemic cardiomyopathy. Clin Infect Dis Off Publ Infect Dis Soc Am. 1995;21:1315&#x2013;1317.</Citation><ArticleIdList><ArticleId IdType="pubmed">8589166</ArticleId></ArticleIdList></Reference><Reference><Citation>Oldstone MBA. Viral persistence: parameters, mechanisms and future predictions. Virology. 2006;344:111&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">16364742</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunningham L, Bowles NE, Lane RJM, Dubowitz V, Archard LC. Persistence of enteroviral RNA in chronic fatigue syndrome is associated with the abnormal production of equal amounts of positive and negative strands of enteroviral RNA. J Gen Virol. 1990;71:1399&#x2013;1402.</Citation><ArticleIdList><ArticleId IdType="pubmed">2161907</ArticleId></ArticleIdList></Reference><Reference><Citation>Ertel KJ, Brunner JE, Semler BL. Mechanistic consequences of hnRNP C binding to both RNA termini of poliovirus negative-strand RNA intermediates. J Virol. 2010;84:4229&#x2013;4242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2863767</ArticleId><ArticleId IdType="pubmed">20164237</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma N, Ogram SA, Morasco BJ, Spear A, Chapman NM, Flanegan JB. Functional role of the 5&#x2019;terminal cloverleaf in Coxsackievirus RNA replication. Virology. 2009;393:238&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">19732932</ArticleId></ArticleIdList></Reference><Reference><Citation>Parsley TB, Towner JS, Blyn LB, Ehrenfeld E, Semler BL. Poly (rC) binding protein 2 forms a ternary complex with the 5&#x2019;-terminal sequences of poliovirus RNA and the viral 3CD proteinase. RNA N Y N. 1997;3:1124&#x2013;1134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1369554</ArticleId><ArticleId IdType="pubmed">9326487</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K-S, Chapman NM, Tracy S. Replication of coxsackievirus B3 in primary cell cultures generates novel viral genome deletions. J Virol. 2008;82:2033&#x2013;2037.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2258713</ArticleId><ArticleId IdType="pubmed">18057248</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim B-K, Peter AK, Xiong D, Narezkina A, Yung A, Dalton ND, Hwang K-K, Yajima T, Chen J, Knowlton KU. Inhibition of Coxsackievirus-associated dystrophin cleavage prevents cardiomyopathy. J Clin Invest. 2013;123:5146&#x2013;5151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3859391</ArticleId><ArticleId IdType="pubmed">24200690</ArticleId></ArticleIdList></Reference><Reference><Citation>Maghsoudi N, Tafreshi NK, Khodagholi F, Zakeri Z, Esfandiarei M, Hadi-Alijanvand H, Sabbaghian M, Maghsoudi AH, Sajadi M, Zohri M, Moosavi M, Zeinoddini M. Targeting enteroviral 2A protease by a 16-mer synthetic peptide: inhibition of 2Apro-induced apoptosis in a stable Tet-on HeLa cell line. Virology. 2010;399:39&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">20096913</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>